Indian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...

Cipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply ...

Cipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth. Brokerages have differi...

“Sun, Cipla, Lupin being market leaders, should be able to do well. Most of these companies have actually added on the Street last year. Wh...

One of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was made possi...

One of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was possible b...

Leading pharma companies Sun Pharma, Lupin, Cadila Healthcare, Torrent Pharma, Dr Reddy’s Labs and Cipla have come together to invest in a ...

Though India is known as the pharmacy of the world for its massive production capacities of both generic drugs and vaccines, China accounte...

State governments typically coordinate drug orders for public hospitals, where most Covid-19 patients are treated. In some states, includin...

“The concerns over supply of Chinese raw material proved to be ill-founded,” Nilesh Gupta, managing director of Lupin, told ET.

The company, aspiring to become a lung leader globally, could not escape the impact of coronavirus.

Investors may keenly follow Sun Pharma earnings for updates on Halol OAI.

Tthe brokerage has downward revised its FY21 and FY22 forecasts on Cipla, having knocked off Voltaren sales number and pushed Albuterol inh...

“Right now, we are good on supplies, but obviously it cannot continue indefinitely,” Sharma added.